[Form 4] Guardant Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Myrtle S. Potter, a director of Guardant Health, Inc. (GH), reported an RSU vesting and a subsequent small sale of shares. On 09/15/2025 a restricted stock unit award vested for 68 shares at no cash price. Two days later, on 09/17/2025, the reporting person sold 26 shares at $55.63 per share. Beneficial ownership reported after the sale was 18,281 shares on a direct basis. The filing was executed by attorney-in-fact John G. Saia on 09/17/2025. The RSU award follows a vesting schedule that began with 25% vesting on October 15, 2022, with the remaining 75% vesting monthly over the following three years.

Positive

• 68 RSU shares vested on 09/15/2025, reflecting compensation realization rather than an open-market acquisition
• Clear vesting schedule disclosed: 25% vested on October 15, 2022 and remaining 75% vesting monthly over three years

Negative

• Sale of 26 shares on 09/17/2025 at $55.63 per share, reducing direct holdings from 18,307 to 18,281 shares

Insights

Financial Analyst

TL;DR: Routine director RSU vesting followed by a small sale; immaterial to company valuation.

The filing shows a non-cash vesting of 68 RSU shares and a subsequent sale of 26 shares at $55.63, leaving 18,281 shares beneficially owned directly. This pattern is consistent with periodic RSU vesting and partial disposition for liquidity or tax purposes. The transaction size is minor relative to typical public-company float and does not indicate management change or strategic shift. Investors should view this as a routine insider liquidity event tied to compensation vesting.

Corporate Governance Expert

TL;DR: Disclosure is timely and standard; vesting schedule and signature by attorney-in-fact are properly noted.

The Form 4 discloses the vesting mechanics and a small sale, with the relationship to the issuer identified as Director. The explanation clarifies the RSU vesting cadence beginning October 15, 2022, and the filing includes an attorney-in-fact signature dated 09/17/2025. There are no indications of departures, additional grants, or concentrated disposals that would raise governance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

POTTER MYRTLE S

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2025		M		68	A	$0	18,307	D
Common Stock	09/17/2025		S		26	D	$55.63	18,281	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	09/15/2025		M			68	(1)	(2)	Common Stock	68	$0	69	D

Explanation of Responses:

1. The restricted stock unit award vested as to 25% of the shares subject to such award on October 15, 2022. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of October 15, 2022 during the three-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Myrtle S. Potter	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Myrtle S. Potter report on Form 4 for GH?

The Form 4 reports a vesting of 68 RSU shares on 09/15/2025 and a sale of 26 shares on 09/17/2025 at $55.63.

How many Guardant Health (GH) shares does the reporting person own after the transactions?

Following the reported transactions, the reporting person beneficially owned 18,281 shares on a direct basis.

What is the vesting schedule for the RSU award referenced in the filing?

The award vested 25% on October 15, 2022, with the remaining 75% vesting in substantially equal monthly installments over the next three years.

Who signed the Form 4 and when was it filed?

The form was signed by John G. Saia as attorney-in-fact for Myrtle S. Potter on 09/17/2025.

What relationship does the reporting person have with Guardant Health (GH)?

The reporting person is listed as a Director of Guardant Health.